Form 4: Beam Therapeutics President Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Giuseppe Ciaramella, President of Beam Therapeutics, sold shares to cover tax withholding obligations related to vested restricted stock units.
Summary
- Giuseppe Ciaramella, President of Beam Therapeutics, sold 7,434 shares of common stock on April 1, 2025.
- The sale was executed at a weighted average price of $18.3506 per share, with individual transactions ranging from $17.76 to $18.38.
- The shares were sold to cover tax withholding obligations upon the vesting of restricted stock units.
- The sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on May 23, 2023.
- Following the transaction, Ciaramella directly owns 190,216 shares of Beam Therapeutics.
Sentiment
Score: 5
Explanation: The document describes a routine transaction (selling shares to cover taxes) and doesn't contain any information that would significantly impact investor sentiment positively or negatively.
Industry Context
Sales of shares to cover tax obligations are a routine part of equity compensation for executives at publicly traded companies.
Stakeholder Impact
- The sale of shares by an executive could have a minor negative impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.
Key Dates
| Date | Description |
|---|---|
| March 31, 2021 | Vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ('BEAM') 2019 Equity Incentive Plan |
| March 31, 2022 | Vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ('BEAM') 2019 Equity Incentive Plan |
| March 31, 2023 | Vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ('BEAM') 2019 Equity Incentive Plan |
| May 23, 2023 | Adoption date of Rule 10b5-1 trading plan. |
| March 31, 2024 | Vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ('BEAM') 2019 Equity Incentive Plan |
| April 01, 2025 | Date of stock sale. |
| April 03, 2025 | Date of Form 4 filing. |
Keywords
Beam Therapeutics, Ciaramella, insider trading, Form 4, stock sale, tax obligations, Rule 10b5-1, equity incentive plan, restricted stock units
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.